[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL343378A1 - Paroxetine maleate - Google Patents

Paroxetine maleate

Info

Publication number
PL343378A1
PL343378A1 PL99343378A PL34337899A PL343378A1 PL 343378 A1 PL343378 A1 PL 343378A1 PL 99343378 A PL99343378 A PL 99343378A PL 34337899 A PL34337899 A PL 34337899A PL 343378 A1 PL343378 A1 PL 343378A1
Authority
PL
Poland
Prior art keywords
paroxetine maleate
paroxetine
maleate
Prior art date
Application number
PL99343378A
Other languages
English (en)
Inventor
Victor Witold Jacewicz
Alan David Jones
John Man
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807627.6A external-priority patent/GB9807627D0/en
Priority claimed from GBGB9823856.1A external-priority patent/GB9823856D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PL343378A1 publication Critical patent/PL343378A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL99343378A 1998-04-09 1999-04-09 Paroxetine maleate PL343378A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807627.6A GB9807627D0 (en) 1998-04-09 1998-04-09 Novel compounds
GBGB9823856.1A GB9823856D0 (en) 1998-10-30 1998-10-30 Novel compound

Publications (1)

Publication Number Publication Date
PL343378A1 true PL343378A1 (en) 2001-08-13

Family

ID=26313449

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99343378A PL343378A1 (en) 1998-04-09 1999-04-09 Paroxetine maleate

Country Status (18)

Country Link
EP (1) EP1073652A1 (xx)
JP (1) JP2002511466A (xx)
KR (1) KR20010042552A (xx)
CN (1) CN1305474A (xx)
AP (1) AP2000001950A0 (xx)
AU (1) AU3433499A (xx)
BG (1) BG104914A (xx)
BR (1) BR9909529A (xx)
CA (1) CA2327450A1 (xx)
EA (1) EA200001050A1 (xx)
HU (1) HUP0103651A3 (xx)
ID (1) ID26879A (xx)
IL (1) IL138920A0 (xx)
NO (1) NO20005037L (xx)
PL (1) PL343378A1 (xx)
SK (1) SK15032000A3 (xx)
TR (1) TR200002939T2 (xx)
WO (1) WO1999052901A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
ITTO20060143A1 (it) * 2006-02-28 2007-09-01 Bridgestone Corp Pneumatico

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물

Also Published As

Publication number Publication date
EP1073652A1 (en) 2001-02-07
BG104914A (en) 2001-10-31
CA2327450A1 (en) 1999-10-21
KR20010042552A (ko) 2001-05-25
IL138920A0 (en) 2001-11-25
NO20005037L (no) 2000-12-05
HUP0103651A3 (en) 2002-12-28
EA200001050A1 (ru) 2001-04-23
HUP0103651A2 (en) 2002-08-28
AU3433499A (en) 1999-11-01
ID26879A (id) 2001-02-15
WO1999052901A1 (en) 1999-10-21
AP2000001950A0 (en) 2000-12-31
JP2002511466A (ja) 2002-04-16
BR9909529A (pt) 2000-12-12
TR200002939T2 (tr) 2001-02-21
CN1305474A (zh) 2001-07-25
SK15032000A3 (sk) 2001-04-09
NO20005037D0 (no) 2000-10-06

Similar Documents

Publication Publication Date Title
GB2352395B (en) Paroxetine methanesulfonate
GB2331534B (en) Centralizer
ZA992191B (en) Piperidine derivatives.
IL137329A0 (en) Vla-4 antagonists
ZA200101830B (en) Piperidine derivatives.
ZA988938B (en) Amorphous paroxetine composition.
PL343378A1 (en) Paroxetine maleate
HU9904086D0 (en) New 4-substituted piperidines
GB9818418D0 (en) Sub
PL343095A1 (en) Paroxetine compositions
HUP0101931A3 (en) Novel formulation containing paroxetine
PL343677A1 (en) Paroxetine ascorbate
GB9803577D0 (en) Stays
HUP0101215A3 (en) Chrystalline form of paroxetine
AU137971S (en) Implant
IL139594A0 (en) Novel formulation containing paroxetine
TW401868U (en) Improved drill
GB9904614D0 (en) Piperidines
AU135297S (en) Top
GB9803376D0 (en) Packer
AU6459800A (en) Paroxetine
GB9810175D0 (en) Phosphate-medicated cyclization
AU138672S (en) Bowl
PL341899A1 (en) Vla-4 antagonists
AU139580S (en) Extension lead

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)